New antithrombotic agents

被引:23
作者
Weitz, JI [1 ]
Hirsh, J [1 ]
机构
[1] Hamilton Civ Hosp, Res Ctr, Hamilton, ON L8V 1C3, Canada
关键词
D O I
10.1378/chest.114.5_Supplement.715S
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
引用
收藏
页码:715S / 727S
页数:13
相关论文
共 140 条
[1]   LOW-MOLECULAR-WEIGHT, NONPEPTIDE FIBRINOGEN RECEPTOR ANTAGONISTS [J].
ALIG, L ;
EDENHOFER, A ;
HADVARY, P ;
HURZELER, M ;
KNOPP, D ;
MULLER, M ;
STEINER, B ;
TRZECIAK, A ;
WELLER, T .
JOURNAL OF MEDICINAL CHEMISTRY, 1992, 35 (23) :4393-4407
[2]  
AOKI Y, 1994, THROMB HAEMOSTASIS, V71, P452
[3]   TAFI, or plasma procarboxypeptidase B, couples the coagulation and fibrinolytic cascades through the thrombin-thrombomodulin complex [J].
Bajzar, L ;
Morser, J ;
Nesheim, M .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1996, 271 (28) :16603-16608
[4]   PURIFICATION AND CHARACTERIZATION OF TAFI, A THROMBIN-ACTIVABLE FIBRINOLYSIS INHIBITOR [J].
BAJZAR, L ;
MANUEL, R ;
NESHEIM, ME .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1995, 270 (24) :14477-14484
[5]   PHARMACOKINETICS AND PHARMACODYNAMICS OF MK-383, A SELECTIVE NONPEPTIDE PLATELET GLYCOPROTEIN-IIB/IIIA RECEPTOR ANTAGONIST, IN HEALTHY-MEN [J].
BARRETT, JS ;
MURPHY, G ;
PEERLINCK, K ;
LEPELEIRE, ID ;
GOULD, RJ ;
PANEBIANCO, D ;
HAND, E ;
DECKMYN, H ;
VERMYLEN, J ;
ARNOUT, J .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1994, 56 (04) :377-388
[6]  
Bata I, 1997, CIRCULATION, V96, P769
[7]  
Bazzino O, 1998, NEW ENGL J MED, V338, P1498
[8]  
Bazzino O, 1998, NEW ENGL J MED, V338, P1488
[9]   PREVENTION OF OCCLUSIVE CORONARY-ARTERY THROMBOSIS BY A MURINE MONOCLONAL-ANTIBODY TO PORCINE VONWILLEBRAND-FACTOR [J].
BELLINGER, DA ;
NICHOLS, TC ;
READ, MS ;
REDDICK, RL ;
LAMB, MA ;
BRINKHOUS, KM ;
EVATT, BL ;
GRIGGS, TR .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1987, 84 (22) :8100-8104
[10]   Enhanced protein C activation and inhibition of fibrinogen cleavage by a thrombin modulator [J].
Berg, DT ;
Wiley, MR ;
Grinnell, BW .
SCIENCE, 1996, 273 (5280) :1389-1391